JP2020510693A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510693A5
JP2020510693A5 JP2019556790A JP2019556790A JP2020510693A5 JP 2020510693 A5 JP2020510693 A5 JP 2020510693A5 JP 2019556790 A JP2019556790 A JP 2019556790A JP 2019556790 A JP2019556790 A JP 2019556790A JP 2020510693 A5 JP2020510693 A5 JP 2020510693A5
Authority
JP
Japan
Prior art keywords
cyclopropyl
benzo
imidazole
pyridazine
difluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019556790A
Other languages
English (en)
Japanese (ja)
Other versions
JP7227157B2 (ja
JP2020510693A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/068190 external-priority patent/WO2018125800A2/en
Publication of JP2020510693A publication Critical patent/JP2020510693A/ja
Publication of JP2020510693A5 publication Critical patent/JP2020510693A5/ja
Priority to JP2023018482A priority Critical patent/JP7611278B2/ja
Application granted granted Critical
Publication of JP7227157B2 publication Critical patent/JP7227157B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019556790A 2016-12-29 2017-12-22 金属酵素阻害剤化合物 Active JP7227157B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023018482A JP7611278B2 (ja) 2016-12-29 2023-02-09 金属酵素阻害剤化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662440181P 2016-12-29 2016-12-29
US62/440,181 2016-12-29
PCT/US2017/068190 WO2018125800A2 (en) 2016-12-29 2017-12-22 Metalloenzyme inhibitor compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023018482A Division JP7611278B2 (ja) 2016-12-29 2023-02-09 金属酵素阻害剤化合物

Publications (3)

Publication Number Publication Date
JP2020510693A JP2020510693A (ja) 2020-04-09
JP2020510693A5 true JP2020510693A5 (enExample) 2021-02-12
JP7227157B2 JP7227157B2 (ja) 2023-02-21

Family

ID=62709109

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556790A Active JP7227157B2 (ja) 2016-12-29 2017-12-22 金属酵素阻害剤化合物
JP2023018482A Active JP7611278B2 (ja) 2016-12-29 2023-02-09 金属酵素阻害剤化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023018482A Active JP7611278B2 (ja) 2016-12-29 2023-02-09 金属酵素阻害剤化合物

Country Status (14)

Country Link
US (3) US10085984B2 (enExample)
EP (2) EP4311577A3 (enExample)
JP (2) JP7227157B2 (enExample)
KR (1) KR102690885B1 (enExample)
CN (2) CN110691598A (enExample)
AU (2) AU2017387033B2 (enExample)
CA (1) CA3055292A1 (enExample)
DK (1) DK3562487T3 (enExample)
ES (1) ES2967119T3 (enExample)
FI (1) FI3562487T3 (enExample)
MX (2) MX2019007892A (enExample)
RU (1) RU2764666C2 (enExample)
TW (1) TWI786078B (enExample)
WO (1) WO2018125800A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136427B (zh) * 2012-01-20 2017-03-01 威尔金制药有限公司 金属酶抑制剂化合物
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
RU2764666C2 (ru) 2016-12-29 2022-01-19 Селенити Терапьютикс (Бермуда), Лтд. Соединения, ингибирующие металлоферменты
AU2020207051B2 (en) * 2019-01-08 2025-07-24 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
GB201901757D0 (en) 2019-02-08 2019-03-27 Syngenta Crop Protection Ag Herbicidal compounds
WO2021233861A1 (en) 2020-05-19 2021-11-25 Bayer Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
EP4165038A1 (en) 2020-06-10 2023-04-19 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides
AT524288B1 (de) * 2020-09-16 2024-05-15 Gatan Inc Computergestütztes Verfahren zur Bestimmung eines Elementanteiles eines Bestimmungselementes kleiner Ordnungszahl, insbesondere eines Li-Anteiles, und Vorrichtung zur Datenverarbeitung hierzu
WO2025157275A1 (zh) * 2024-01-26 2025-07-31 箕星药业香港有限公司 金属酶抑制剂化合物的固体形式
CN120463643B (zh) * 2025-05-27 2025-11-28 咸阳职业技术学院 一种2-环丙基胺基-3-硝基-6-氯吡啶的合成方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939916A1 (de) 1979-10-02 1981-04-23 Hoechst Ag, 6000 Frankfurt Quaternierte, verbrueckte benzimidazolyl-benzimidazole, verfahren zu deren herstellung und deren verwendung
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
EP0431519B1 (en) 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
WO1993011938A1 (en) 1991-12-18 1993-06-24 Minnesota Mining And Manufacturing Company Multilayered barrier structures
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
EP1441725A1 (en) 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
BR0306785A (pt) * 2002-01-07 2004-11-09 Eisai Co Ltd Deazapurinas e seus usos
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
KR101099303B1 (ko) 2005-01-28 2011-12-26 주식회사 대웅제약 신규한 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
AU2006311914C1 (en) 2005-11-03 2013-10-24 Chembridge Corporation Heterocyclic compounds as tyrosine kinase modulators
US20080027044A1 (en) 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
WO2008128968A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
US7737175B2 (en) 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
CN101687815A (zh) 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成
JP5142836B2 (ja) 2007-07-02 2013-02-13 オセ−テクノロジーズ ビーブイ 走査画像要素位置合わせ方法
EP2205070A4 (en) 2007-10-04 2011-01-12 Merck Sharp & Dohme N-HYDROXY-NAPHTHALINE-DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONDEACETYLASE INHIBITORS
AU2009212135B2 (en) 2008-02-07 2014-08-21 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
GB0821994D0 (en) 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
WO2010130796A1 (en) 2009-05-15 2010-11-18 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
ES2663351T3 (es) 2009-11-17 2018-04-12 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
US9382226B2 (en) * 2010-07-21 2016-07-05 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
DK2624832T3 (en) 2010-10-08 2018-01-08 Vib Vzw HDAC INHIBITORS FOR TREATMENT OF CHARCOT-MARIE-TOOTHS DISEASE
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
WO2013033901A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
US9883909B2 (en) * 2012-03-08 2018-02-06 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and systems for treatment of hyperaldosteronism
CN103626783B (zh) * 2012-08-22 2016-06-08 中国科学院上海药物研究所 双环稠杂环化合物及其用途和药物组合物
WO2014179303A1 (en) 2013-04-29 2014-11-06 The General Hospital Corporation Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
WO2015188369A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
TR201907755T4 (tr) * 2014-10-15 2019-06-21 Boehringer Ingelheim Int Aldosteron sentaz inhibitörleri.
WO2018118781A1 (en) * 2016-12-20 2018-06-28 Fmc Corporation Fungicidal oxadiazoles
RU2764666C2 (ru) 2016-12-29 2022-01-19 Селенити Терапьютикс (Бермуда), Лтд. Соединения, ингибирующие металлоферменты
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
AU2020207051B2 (en) 2019-01-08 2025-07-24 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds

Similar Documents

Publication Publication Date Title
JP2020510693A5 (enExample)
RU2018123779A (ru) Новые соединения
JP2005538100A5 (enExample)
JP2015531366A5 (enExample)
JP2020503299A5 (enExample)
JP2017530187A5 (enExample)
PE20221724A1 (es) Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr)
JP2017502940A5 (enExample)
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
JP2016525076A5 (enExample)
PE20160115A1 (es) Compuestos derivados de imidazol como inhibidores de protein quinasa
JP2012528166A5 (enExample)
JP2013510125A5 (enExample)
JP2016531121A5 (enExample)
RU2018121499A (ru) Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
MY148322A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
EA200800182A1 (ru) Циклические анилинопиридинотриазины в качестве ингибиторов gsk-3
JP2018515438A5 (enExample)
JP2016525075A5 (enExample)
JP2016523269A5 (enExample)
JP2005535586A5 (enExample)
JP2015514808A5 (enExample)
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
JP2019081762A5 (enExample)